Sai Life Sciences Limited Q1 FY26 results press release summary

Results press release of 8 Aug 2025, summarised by AI from the filing.

Q1FY26 revenue from operations ₹496 cr (Q1FY25: ₹280 cr, +77% YoY), driven primarily by strong growth in the CDMO segment.

Key takeaways

1. Revenue Q1FY26 revenue from operations ₹496 cr (Q1FY25: ₹280 cr, +77% YoY), driven primarily by strong growth in the CDMO segment.
2. Guidance Additional 200 KL production capacity at Unit IV, Bidar to be ready by Q3FY27.
3. Change Commenced commercial operations at Bidar Unit IV (PB-11 Phase II), adding ~91 KL capacity and taking total manufacturing capacity to ~700 KL.
4. Driver CDMO segment revenue grew 113% YoY and Discovery revenue rose 38% YoY, enabled by deeper engagement with global clients.
5. Risk Macroeconomic uncertainty and broader industry cycles could affect performance.

Original filing on BSE

Sai Life Sciences Limited Q1 FY27 results

As filed: Revenue ₹554 cr (+12% year on year), EBITDA ₹148 cr (+22% year on year), PAT ₹73.3 cr (+22% year on year), EBITDA margin 26.7% (+231 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹602 cr (+4% year on year), EBITDA ₹177 cr (+12% year on year), PAT ₹104 cr (+18% year on year), EBITDA margin 29.3% (+225 bps). Score 53 of 100, In line with trend. EBITDA margin rose 225 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +6.5% in 30 days (Nifty 500: −3.8%).
• Q3 FY26: Revenue ₹556 cr (+26% year on year), EBITDA ₹188 cr (+57% year on year), PAT ₹100 cr (+86% year on year), EBITDA margin 33.8% (+649 bps). Score 92 of 100, Above trend. EBITDA margin rose 649 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +21.7% in 30 days (Nifty 500: +1.5%).
• Q2 FY26: Revenue ₹527 cr, EBITDA ₹140 cr, PAT ₹83.0 cr, EBITDA margin 26.6%. Not scored. No result for the same quarter last year. Share price after the results: −5.0% in 29 days (Nifty 500: +1.4%).
• Q1 FY26: Revenue ₹483 cr, EBITDA ₹113 cr, PAT ₹58.0 cr, EBITDA margin 23.4%. Not scored. No result for the same quarter last year. Share price after the results: +8.7% in 29 days (Nifty 500: +0.6%).
• Q4 FY25: Revenue ₹567 cr, EBITDA ₹153 cr, PAT ₹90.0 cr, EBITDA margin 27.0%. Not scored. No result for the same quarter last year. Share price after the results: +6.1% in 30 days (Nifty 500: +2.5%).
• Q3 FY25: Revenue ₹429 cr, EBITDA ₹112 cr, PAT ₹51.0 cr, EBITDA margin 26.1%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Sai Life Sciences Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Results deck (7 Aug 2026), Results press release (6 Aug 2026)
• Q4 FY26: Results deck (15 May 2026), Results press release (14 May 2026)
• Q3 FY26: Results deck (6 Feb 2026), Results press release (5 Feb 2026)
• Q2 FY26: Results deck (7 Nov 2025), Results press release (6 Nov 2025)
• Q1 FY26: Results deck (8 Aug 2025), Results press release (8 Aug 2025)
• Q4 FY25: Earnings call (14 May 2025), Results deck (14 May 2025), Results press release (14 May 2025)